Department of Materials, Department of Bioengineering, and Institute for Biomedical Engineering, Imperial College London, London SW7 2AZ, United Kingdom.
Department of Materials, Department of Bioengineering, and Institute for Biomedical Engineering, Imperial College London, London SW7 2AZ, United Kingdom.
Adv Drug Deliv Rev. 2018 May;130:12-16. doi: 10.1016/j.addr.2018.06.017. Epub 2018 Jun 28.
Extracellular vesicles (EVs), sub-micron vectors used in intercellular communication, have demonstrated great promise as natural drug delivery systems. Recent reports have detailed impressive in vivo results from the administration of EVs pre-loaded with therapeutic cargo, including small molecules, nanoparticles, proteins and oligonucleotides. These results have sparked intensive research interest across a huge range of disease models. There are, however, enduring limitations that have restricted widespread clinical and pharmaceutical adoption. In this perspective, we discuss these practical and biological concerns, critically compare the relative merit of EVs and synthetic drug delivery systems, and highlight the need for a more comprehensive understanding of in vivo transport and delivery. Within this framework, we seek to establish key areas in which EVs can gain a competitive advantage in order to provide the tangible added value required for widespread translation.
细胞外囊泡 (EVs) 是用于细胞间通讯的亚微米载体,作为天然药物传递系统具有巨大的应用潜力。最近的研究报告详细介绍了 EV 负载治疗性 cargo(包括小分子、纳米颗粒、蛋白质和寡核苷酸)给药的令人印象深刻的体内结果。这些结果激发了广泛的研究兴趣,涉及各种疾病模型。然而,仍然存在限制因素,这些因素限制了它们在临床和制药方面的广泛应用。在本文中,我们讨论了这些实际和生物学方面的关注,批判性地比较了 EVs 和合成药物传递系统的相对优势,并强调了需要更全面地了解体内运输和传递。在这个框架内,我们旨在确定 EVs 可以获得竞争优势的关键领域,以提供广泛转化所需的切实附加值。